marketing pharmaceutical products containing the
active pharmaceutical ingredient (API) Vildagliptin (subject matter of
the suit patent), under co-marketing agreement with Plaintiff ... superior and high quality. Plaintiff no. 2 markets in
India Vidagliptin and Vildagliptin + Metformin Hydrochloride in
combination under the brands GALVUS and GALVUSMET
respectively. Similarly
Single Judge
has noted that the patent relates to a pharmaceutical product Vildagliptin.
It treats Type 2 Diabetes Mellitus. The learned Single Judge has noted ... have three
pending patent applications before the Indian Patent Office relating to
Vildagliptin formulations, Vildagliptin and Metformin hydrochloride
formulations under the brands GALVUS and GALVUSMET
more effective and longer lasting than the other major
DPP-4 inhibitors vildagliptin, sitagliptin, saxagliptin and
alogliptin, and is thus potent at low therapeutic doses
ZAVAMET Type 2 diabetes - Registered- 1400/ pf
METFORMIN + Used since pg. 1409
VILDAGLIPTIN 10.09.2019
Valid upto
10.09.2029
Pg. 1398/ pdf
pg. 131407
19 VIVAMET Type
prices of the oral diabetes drugs containing the
Active Pharmaceutical Ingredient (API) Vildagliptin. In addition to
LPA 658/2018 Page 2 of 12
the pricing
patent which covers the Type 2
Diabetes Mellitus (T2DM) compound named 'Vildagliptin'. The sum
and substance of the ground taken by the Defendant
prices of the oral diabetes drugs containing the Active Pharmaceutical
Ingredient (API) Vildagliptin. In addition to the pricing data furnished by
NPPA
said notes read
as under:-
"b. Sitagliptin 100mg/Vildagliptin 100mg/Saxagliptin
5mg shall be considered equivalent for L-1 calculation; the
demand of Gliptin ... that in note (b), three drugs
have been mentioned, namely, Sitagliptin, Vildagliptin and Saxagliptin and that
as per the note, these three drugs
offer for sale pharmaceutical products,
compounds or formulations or active ingredients containing Vildagliptin,
that may amount to infringement of the aforesaid patent, the present suit
